Sign In
Step 1
Draft
Step 2
Unite with Fellow Investors
Step 3
Choose the Best Attorney
Step 4
Provide Documents
Step 5
Follow Case Progress
Step 6
Get Payout
Metagenomi.PRVT
id: 1359

Metagenomi Therapeutics ($MGX) $7.5 Million Investor Settlement

The settlement terms have been submitted to the court for approval.
$75,000,000
Cash Settlement
N.D. California
Court
5:24-cv-06765
Case number
02/09/2024
Class period Start
05/01/2024
Class period End

Metagenomi Therapeutics agreed to a $7.5 million settlement resolving claims that its IPO materials misled investors about the status and progress of its collaboration with Moderna.

Outline:

Metagenomi completed its initial public offering in February 2024 at $15 per share. Investors allege that the company’s IPO materials contained misleading statements and omissions about its collaboration with Moderna. The lawsuit claims investors were not given an accurate picture of the status and progress of the collaboration’s preclinical programs. Metagenomi and the individual defendants have agreed to resolve the claims for $7.5 million.

Timeline:

  • January 5, 2024: Metagenomi filed the registration statement used for its initial public offering.

  • February 9, 2024: Metagenomi common stock began trading on Nasdaq under the ticker MGX at an IPO price of $15 per share.

  • February 12, 2024: Metagenomi filed the prospectus used in connection with its IPO.

  • February 13, 2024: Metagenomi completed its IPO, through which 6.25 million shares were issued and sold.

  • September 26, 2024: Investors filed a securities lawsuit alleging that Metagenomi’s IPO materials contained misleading statements and omissions.

  • November 18, 2026: The parties entered into a formal $7.5 million settlement agreement.

Background:

Metagenomi is a biotechnology company that completed its initial public offering in February 2024. The company issued 6.25 million shares at $15 per share, with its common stock beginning to trade on Nasdaq under the ticker MGX.

The company’s IPO registration statement discussed Metagenomi’s collaboration with Moderna and the progress of preclinical programs being developed through that relationship. Investors later alleged that those disclosures did not accurately describe the status of the collaboration and omitted material information about the progress of the programs.

The lawsuit alleges that investors purchased Metagenomi shares based on IPO materials containing untrue statements or material omissions. The claims were brought under Sections 11 and 15 of the Securities Act of 1933 and did not allege fraud, recklessness, or intentional misconduct.

In March 2026, the Court allowed certain claims concerning statements and omissions about the Moderna collaboration to proceed. The parties later entered mediation and reached an agreement in principle on October 21, 2026.

What Can Investors Expect Now?

Metagenomi Therapeutics agreed to a $7.5 million settlement resolving claims that its IPO materials misled investors about the status and progress of its collaboration with Moderna.

If you were damaged due to this situation, you can file for a payout and get your share of the settlement. You can check if you are eligible and other details in the FAQ section.

Case Type
US Securities Class Action
Case Status
Stipulative Settlement
Alleged Offence
Misleading Statements, 
Financial Misrepresentation, 
Failure to Disclose, 
Omissions
Suspected Party
Directors, 
Management
Security Type
Stocks
Trade Direction
Long
Payout per Share
1.2
Filing date
09/26/2024
Lead Plaintiff Deadline
11/25/2024
Plaintiffs
Kevin Vreeland
Attorneys
Levi & Korsinsky, LLP
Defendants
Brian C. Thomas; Pamela Wapnick; Juergen Eckhardt
Administrator
Strategic Claims Services
Attorney fee
$2,999,750
Trades matching type
FIFO

Frequently Asked Questions